Exploring the Potential of Stellate Ganglion Block in Managing Menopausal Symptoms
A recent study published in the Cleveland Clinic Journal of Medicine explores the potential use of stellate ganglion block (SGB) as a non-hormonal treatment for vasomotor symptoms (VMS) commonly experienced during menopause. The research sheds light on the effectiveness of SGB in managing these symptoms, particularly in perimenopausal and postmenopausal women who have severe symptoms refractory to more conservative care.
HCN Medical Memo
The findings from this study could have significant implications for healthcare professionals working with perimenopausal and postmenopausal women. Understanding the potential benefits and risks associated with SGB could help physicians, pharmacists, and nurses provide more informed care and offer alternative treatment options for patients who are unable or choose not to use hormone therapy.
- VMS, also known as hot flashes, hot flushes, and night sweats, are common symptoms of menopause, affecting approximately 60% to 80% of women.
- SGB is a well-established treatment for pain and is now being considered as a promising alternative non-hormonal treatment for VMS.
- Data indicate that SGB reduces the frequency of VMS by 4% to 90%, with few adverse events.
- Despite its potential, SGB is currently recommended with caution due to a lack of long-term clinical trial data on efficacy and safety.
A 2015 article reported that healthcare costs for women with VMS were $1,346 higher than for their VMS-free counterparts, and women with VMS experienced lower productivity, with an indirect cost via work absenteeism costing roughly $770 per year.
More in OBGYN